Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be diagnosed with CKD and creatinine clearance less than 60 ml / minute secondary to hypertension and / or diabetes.~* Age over 18 years~Exclusion Criteria:~* Malignant neoplasms whose last treatment was less than 5 years~* Having received antibiotics for any reason during the month prior to enrollment~* Have received probiotics in the last 3 months~* Have been diagnosed with Clostridium difficile infection in the last year~* Have been previously submitted to TMF~* Having presented ERC exacerbations during the 3 months prior or present at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Faecal microbiota transplant (Type: EXPERIMENTAL): This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).